SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM

Endocrine Practice

Volumn 21, Issue 12, 2015, Pages 1315-1322

  Saroka, Rachel M ^a   Kane, Michael P ^a   Busch, Robert S ^b   Watsky, Jay ^b   Hamilton, Robert A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; CHOLESTEROL; CREATININE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA; AGED; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84979812565     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP15877.OR     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.
2. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38:S1-S93.
3. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36:2271-2279.
4. Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2014;15:2565-2585.
5. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330-339.
6. Vivan EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context 2014;3:212264.
7. Whalen K, Miller S, Onge ES. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther. 2015;37:1150-1166.
8. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-382.
9. Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Obes Metab. 2014;7:107-120.
10. Wysham C, Grimm M, Chen S. Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obes Metab. 2013;15:871-881.
11. Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with Type 2 diabetes mellitus. Postgrad Med. 2013;125:92-100.
12. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020-1031.
13. Forst T, Guthrie R, Goldenburg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467-477.
14. Bell DS. The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss. Am J Case Rep. 2014;15:152-154.
15. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for Type 2 diabetes: a systematic review and meta-Analysis. Ann Intern Med. 2013;159:262-274.
16. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
17. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:186-194.
18. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38:373-375.
19. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38: 376-383.
20. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394-402.
21. Invokana® prescribing information. Janssen Pharmaceuticals, Inc. Titusville, NJ; March 2015.
22. U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Drug safety communications. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed June 11, 2015.
23. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Referrals-document/SGLT2-inhibitori-20/Procedure-started/WC500187926. pdf. Published 12 June 2015. Accessed June 16, 2015.